While lower-count MBL seldom progresses to CLL, large-rely MBL progresses to CLL necessitating therapy at a fee of 1% to 2% annually. Large-rely MBL is distinguished from Rai 0 CLL determined by if the B-cell count is above or below 5 × 109/L. Whilst individuals with both superior-depend MBL and CLL Rai phase 0 are at greater risk of infections an